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Abstract 
Background: The broad antibacterial spectrum of piperacillin/tazobactam makes the combination suitable for the 
treatment of nosocomial bacterial central nervous system (CNS) infections. As limited data are available regarding 
piperacillin CNS exposure in patients without or with low-grade inflammation, a clinical study was conducted (1) to 
quantify CNS exposure of piperacillin by cerebral microdialysis and (2) to evaluate different dosing regimens in order 
to improve probability of target attainment (PTA) in brain.
Methods: Ten acute hemorrhagic stroke patients (subarachnoid hemorrhage, n = 6; intracerebral hemorrhage, 
n = 4) undergoing multimodality neuromonitoring received 4 g piperacillin/0.5 g tazobactam every 8 h by 30-min 
infusions for the management of healthcare-associated pneumonia. Cerebral microdialysis was performed as part of 
the clinical neuromonitoring routine, and brain interstitial fluid samples were retrospectively analyzed for piperacillin 
concentrations after the first and after multiple doses for at least 5 days and quantified by high-performance liquid 
chromatography. Population pharmacokinetic modeling and Monte Carlo simulations with various doses and types 
of infusions were performed to predict exposure. A T>MIC of 50% was selected as pharmacokinetic/pharmacodynamic 
target parameter.
Results: Median peak concentrations of unbound piperacillin in brain interstitial space fluid were 1.16 (range 0.08–
3.59) and 2.78 (range 0.47–7.53) mg/L after the first dose and multiple doses, respectively. A one-compartment model 
with a transit compartment and a lag time (for the first dose) between systemic and brain exposure was appropriate 
to describe the brain concentrations. Bootstrap median estimates of the parameters were: transfer rate from plasma 
to brain (0.32 h−1), transfer rate from brain to plasma (7.31 h−1), and lag time [2.70 h (coefficient of variation 19.7%)]. 
The simulations suggested that PTA would exceed 90% for minimum inhibitory concentrations (MICs) up to 0.5 mg/L 
and 1 mg/L at a dose of 12–16 and 24 g/day, respectively, regardless of type of infusion. For higher MICs, PTA dropped 
significantly.
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Introduction
The broad antibacterial spectrum of the piperacillin/
tazobactam combination would possibly qualify the com-
bination for the treatment of nosocomial bacterial central 
nervous system (CNS) infections [1]. Achievement of 
concentrations suitable for treatment has been reported 
in cerebrospinal fluid (CSF) of meningitis patients [2] at 
a daily dose of 324–436  mg/kg body weight. However, 
patients without generalized meningeal inflammation, 
e.g., those with hydrocephalus, achieved insufficient con-
centrations in CSF [1]. Though CSF concentrations may 
sometimes reflect brain target site concentrations well, 
drug distribution might be different between CSF and 
extracellular fluid (ECF) of the brain [3] and may differ 
manifold between lumbar, ventricular, and cisternal parts 
of the compartment [4, 5]. Conversely, ECF concentra-
tions measured through microdialysis reflect target site 
concentrations well as it only measures free (thus biologi-
cally active) concentrations. In the last two decades, the 
use of microdialysis has evolved quickly and is now an 
integral part of individualized intensive care therapy of 
acute injury patients undergoing multimodal monitoring 
in several centers [6]. Limited data are available regarding 
CNS exposure and related target attainment of antibiot-
ics in patients with acute brain injuries.
Like other beta-lactam antibiotics, piperacillin exhib-
its time-dependent bacterial killing, with T>MIC being 
the relevant pharmacokinetic/pharmacodynamic param-
eter [7]. Cefepime has been reported to show better 
exposure in terms of T>MIC in plasma as well as in CSF 
when administered as a continuous infusion in contrast 
to intermittent infusion in neurosurgical patients with 
postoperative intracranial infections [8]. Piperacillin has 
also been reported to achieve better plasma exposure 
with continuous infusion or extended infusion as com-
pared to intermittent infusion [9–12]. However, it is not 
yet known whether prolonged infusion can improve CNS 
exposure of piperacillin in brain.
Therefore, the objectives of this study were to quantify 
brain ECF concentrations of piperacillin using cerebral 
microdialysis and to develop a model to describe the 
kinetics of its brain exposure in patients without general 
meningeal inflammation. Subsequently, this model was 
used to predict the probability of target attainment (PTA) 
of different doses, types of infusions, and minimum 
inhibitory concentration (MIC) values in order to assess 
the pharmacokinetic fundament for a potential use of 
piperacillin in such patients.
Methods
Patient Selection and Ethical Approval
Ten comatose patients (median [range] age and body 
weight of 52 [32–72] years and 73 [60–95] kg) with acute 
hemorrhagic stroke (subarachnoid hemorrhage [SAH], 
n = 6; intracerebral hemorrhage [ICH], n = 4) admit-
ted to the neurological  intensive care unit (ICU) of the 
Department of Neurology at the Medical University of 
Innsbruck, Austria, requiring invasive multimodal neu-
romonitoring were recruited between October 2010 
and November 2014  (Table  1). Patients were eligible 
if they developed healthcare-associated pneumonia 
and if antibacterial treatment with piperacillin/tazo-
bactam was indicated. Sample size calculation was not 
performed prior to the study. The conduct of this study 
was approved by the Ethics Committee of the Medical 
University of Innsbruck (Approval Numbers AN3898 
285/4.8, AM4091-292/4.6, UN3898 285/4.8) and regis-
tered with the institutional Clinical Trial Center (https 
://ctc.tirol -klini ken.at; study identifier 20131218-868). 
Additionally, the public at the research site was informed 
about the study by notice on the bulletin board at the 
neurological ICU. All provisions of the WMA Declara-
tion of Helsinki in its applicable version were followed, 
and informed consent was obtained from all patients or 
legal representatives according to federal regulations. 
Clinical care of SAH and ICH patients strictly adhered to 
current international guidelines [13–15] with the excep-
tion of nimodipine being administered intravenously in 
SAH patients.
Data Collection, Neuromonitoring, and Sampling 
Procedures
Patient characteristics, medical complications, and 
outcome were prospectively recorded in the respec-
tive institutional SAH and ICH databases. In line with 
international consensus, patients underwent intracranial 
neuromonitoring including measurement of intracra-
nial pressure, brain tissue oxygen tension, and cerebral 
metabolites based on clinical and radiological criteria 
[16]. A cerebral microdialysis catheter (71 High Cut-Off 
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Brain Microdialysis Catheter, M Dialysis AB, Stockholm, 
Sweden) was tunneled and inserted into the white mat-
ter either “perilesionally” (i.e., placement of the catheter 
gold tip within 1  cm to a focal brain lesion) or other-
wise into “normal-appearing tissue.” Isotonic perfusion 
fluid (Perfusion Fluid CNS; M Dialysis AB) was pumped 
through the microdialysis system at a flow rate of 0.3 µL/
min. Hourly samples were analyzed with  ISCUSflex Point-
of-Care Analyzer (M Dialysis AB) for interstitial glucose, 
pyruvate, lactate, and glutamate concentrations and 
frozen thereafter at − 80  °C. During the neuromonitor-
ing period, all patients were intubated and mechanically 
ventilated. To facilitate mechanical ventilation, patients 
received continuous infusions of midazolam plus sufen-
tanil and/or S-ketamine.
Immediately after diagnosis of healthcare-associated 
pneumonia, treatment was initiated according to local 
clinical infectious diseases guidelines with a 30-min 
intravenous infusion of 4  g piperacillin/0.5  g tazobac-
tam (Fresenius Kabi, Graz, Austria) every 8 h. As stated, 
microdialysis samples of brain interstitial fluid were 
obtained in 1  h intervals both after first dose and after 
multiple doses at steady state (median of seven samples 
each). Importantly, cerebral microdialysis was performed 
as part of the clinical neuromonitoring routine and the 
cerebral microdialysis catheter remained in  situ for the 
total neuromonitoring period, usually exceeding the span 
of piperacillin/tazobactam administration.
Determination of In Vitro Recovery
Determination of recovery in vitro was performed using 
identical probes, flow rate, and perfusion fluid as in 
patients. In forward µD experiments, the microdialysis 
catheter was placed into the immersion solution contain-
ing piperacillin/tazobactam (1/0.125 [C1], 10/1.25 [C2], 
or 100/12.5  mg/L [C3]) and was constantly perfused 
with Perfusion Fluid CNS at a flow rate of 0.3 µL/min. In 
reverse µD experiments, immersion solutions contained 
plain Perfusion Fluid CNS, whereas the perfusion solu-
tion contained piperacillin/tazobactam. In both forward 
and reverse µD experiments, µD samples were collected 
over three consecutive sampling intervals of 60  min for 
two different probes.
Analytical Assay
Due to the low flow rate (0.3 µL/min) used during clinical 
microdialysis, a sample volume of 18 µL for each hourly 
sample was obtained out of which approximately 6  µL 
was required for diagnostic purposes. The remaining 
sample volume was not sufficient for two analyses, and 
thus, tazobactam could not be quantified.
Piperacillin concentrations were determined by an iso-
cratic high-performance liquid chromatography (HPLC) 
method with ultraviolet detection at 225  nm which has 
been validated according to the  U.S. Food and Drug 
Administration (FDA) [17] and  European Medicines 
Agency (EMA) [18] recommendations. Quality con-
trol samples of appropriate concentrations prepared 
in Ringer’s solution were analyzed with each assay. The 
coefficient of variation in intra- and inter-assay preci-
sion and accuracy was < 3% based on in-process quality 
controls (80, 8, and 0.8  mg/L). For liquid chromatogra-
phy, an XBridge C18 BEH 2.5µ, 50 × 3 mm column with a 
Nucleoshell RP18 2.7µ, 4 × 3 mm guard column was used 
as the stationary phase. Isocratic elution was carried out 
with 0.1 M  H3PO4, pH 2.7/acetonitrile 75:25 (v/v) using a 
flow rate of 0.4 mL/min. The lower limit of quantification 
(LLOQ) was 0.05  mg/L. Undiluted cerebral microdialy-
sis samples were injected directly into the HPLC sys-
tem, with a defined injection volume of 1–3 µL selected 
according to the expected concentration.
Population Pharmacokinetic Analysis
The NONMEM software (version 7.4.3) [19] was used to 
develop a population pharmacokinetic (PopPK) model 
of piperacillin. Estimations were performed using first-
order conditional estimation with interaction. Different 
models were assessed based on improvement in objective 
function value (drop of ≥ 3.84 corresponding to p < 0.05 
with one degree of freedom, assuming a Chi-squared dis-
tribution), goodness-of-fit plots, and precision of param-
eter estimates from nonparametric bootstrap analysis 
of 1000 samples [20]. Visual predictive checks [21] were 
performed to assess the predictive performance of the 
models. Different models with one, two, and three com-
partments with or without lag time (Tlag) and various 
number of transit compartments were tested to fit the 
brain ECF data.
Because plasma piperacillin concentrations were not 
available, a plasma model with similar study design and 
demographics was selected from the literature [10] to 
drive the brain concentrations in our model. Fixed effects 
parameters as well as inter-individual and intra-individ-
ual variability parameters were fixed in the model.
Dead space of the catheter (distance between semi-
permeable membrane of the probe and catheter outlet) 
was 5.1 µL, and thus, it would take approximately 0.28 h 
for the fluid to reach the outlet based on the flow rate 
(0.3 µL/min) used in the study. To account for the dead 
space, this time was subtracted from the end time of the 
microdialysis time (1-h interval) beforehand in the data-
set. Microdialysis recovery was assumed to be 100% in 
the model based on the results of in  vitro experiments. 
Piperacillin concentrations below LLOQ were retained in 
the dataset and evaluated with M3 and M5 methods [22].
The integrated approach [23] (numerical integration to 
calculate average concentrations during the correspond-
ing microdialysis intervals) was used to model the brain 
data. Plasma protein binding was considered to be lin-
ear and was fixed to 30% according to the plasma phar-
macokinetic model [10]. Inter-individual variability was 
estimated while assuming a log-normal distribution of 
parameters. Additive, proportional, and combined error 
models of residual unexplained variability (RUV) were 
evaluated on the model.
Monte Carlo Simulations and Probability of Target 
Attainment (PTA)
Monte Carlo Simulations (MCS) (5000 simulated sub-
jects) were performed based on the final PopPK model 
of piperacillin at various MIC levels (up to 16 mg/L), for 
three doses (12, 16, and 24 g/day) and three types of infu-
sion (intermittent infusion over 30  min, extended infu-
sion over 3 or 4  h, and continuous infusion). Based on 
plasma data, a pharmacokinetic/pharmacodynamic (PK/
PD) index of fT>MIC of 50% is considered to be essential 
for the optimal activity of piperacillin [24]. Therefore, 
fT>MIC of 50% was selected as PK/PD index for the assess-
ment of probability of target attainment against various 
pathogens according to the MIC distribution suggested 
by the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) for susceptible pathogens [25]. 
Minimum inhibitory concentration required to inhibit 
the growth of 50%  (MIC50) and 90%  (MIC90) of bacte-
ria commonly involved in CNS infections was derived 
from MIC distribution of wild-type microorganisms on 
EUCAST Web site (Table 2) [25].
Sensitivity Analysis
An additional evaluation (sensitivity analysis) was per-
formed to avoid that the selected plasma model would 
bias simulated PTA in brain. To this end, the plasma 
model used was replaced by two other published plasma 
models [26, 27]. New parameters for the brain data were 
estimated, and MCS were done to assess PTA in brain as 
described above. These PTAs were then compared with 
those predicted in the previous simulations.
Results
A total of 130 piperacillin brain concentrations from ten 
acute hemorrhagic stroke patients were available for the 
development of the PopPK model (median 0.95  mg/L 
[range 0.0–7.53]). Median peak concentrations of 
unbound piperacillin in brain interstitial space fluid after 
the first dose were 1.16 (range 0.08–3.59) mg/L. After 
Table 1 Demographic and clinical characteristics of the patients
All values are given as median (inter-quartile range) except gender
APACHE Acute physiology and chronic health evaluation
Parameter Our study Published plasma model used to develop the brain PK 
model [10]
Bolus infusion Bolus infusion Continuous infusion
Gender (male/female) (n) 2/8 5/3 6/2
Weight (kg) 73 (57–88) 80 (74–86) 73 (64–83)
Age (years) 52 (32–71) 41 (22–65) 30 (23–40)
Height (cm) 171 (166–176) 174 (172–180) 176 (171–177)
Piperacillin dose (mg day/kg) 166 229 (204–254) 168 (160–188)
Creatinine clearance (Cockcroft–Gault) (mL/min) 101.5 (63.5–139.5) 88.3(53.3–101.0) 96.7 (31.7–148.3)
APACHE II score on day 1 26 (24–31) 24 (18–26) 20 (16–22)
Stay in intensive care unit (days) 34 (18–50) – –
Table 2 MIC50 and   MIC90 of  piperacillin/tazobactam 
in  mg/L against  pathogens commonly involved in  brain 
infections
MIC50
a and  MIC90
b mean minimum inhibitory concentration required to inhibit 
the growth of 50% and 90% of organisms, respectively. These values have been 
derived from the wild-type distributions of bacteria listed on the EUCAST Web 
site (European Committee on Antimicrobial Susceptibility Testing. Data from the 
EUCAST MIC distribution Web site; Available from: https ://mic.eucas t.org/Eucas 
t2/Searc hCont rolle r/searc h.jsp?actio n=perfo rmSea rch&Begin Index =0&Micdi 
f=mic&Numbe rInde x=50&Antib =251&Speci um=-1)
Pathogen MIC50
a MIC90
b
Haemophilus influenzae 0.016 0.125
Streptococcus agalactiae 0.5 0.5
Streptococcus pneumoniae 0.016 0.5
Neisseria meningitidis 0.5 0.5
Listeria monocytogenes 2 4
Staphylococcus aureus 1 4
Escherichia coli 2 8
Staphylococcus epidermidis 2 16
Pseudomonas aeruginosa 8 128
multiple doses, median peak concentrations at steady 
state increased to 2.78 (range 0.47–7.53) mg/L. Mean 
recovery of piperacillin was 98.3 ± 12.9% (mean/SD).
Brain ECF Pharmacokinetic Model
Brain concentrations of piperacillin were best described 
by a one-compartment model with first-order elimina-
tion. Based on the observed delay in the initial rise of 
brain concentrations (Fig. 1), a lag time (Tlag) and a tran-
sit compartment between plasma and brain were added 
(Fig.  2). Neither Tlag nor the transit compartment alone 
was sufficient to describe the data. Multiple transit com-
partments did not improve the model further. Separate 
population estimates were generated for transfer rate 
from brain to plasma (Kbp) and Tlag after the first dose 
and at steady state. At steady state, Tlag was not signifi-
cantly different from zero; therefore, it was fixed to zero. 
A combined error model best described RUV in the 
model. Median estimates of the parameters with respec-
tive 95% confidence intervals (CI) are given in Table  3 
from bootstrap analysis. In case of  below quantification 
limit (BQL) concentrations, the M5 method performed 
similarly to the gold standard M3 method in terms of 
similar parameter estimates and goodness of fits. M5 was 
preferred for the final model because of numerical diffi-
culties related to the M3 method.  
Model Evaluation
Goodness-of-fit plots (Fig.  3) showed reasonable agree-
ment between brain microdialysate observations and 
individual as well as population predictions for the final 
PopPK model. Conditional weighted residuals were 
uniformly distributed around zero; however, slight 
Fig. 1 Individual piperacillin brain concentration versus time profiles 
showing high variability both after first dose (a) and after multiple 
doses (b)
Fig. 2 Model structure, where CL, Q, Vc, and Vp are elimination clearance, inter-compartmental clearance, volume of distribution of central, and 
peripheral compartment of the plasma model, respectively. The unbound fraction (FU, fixed to 70%) of piperacillin in plasma was used to drive the 
brain concentrations. In the brain model, Kpb, Kbp, and Tlag represent transfer rate from plasma to brain, transfer rate from brain to plasma, and lag 
time, respectively. Continuous line denotes mass transfer between compartments
under-prediction at lower concentrations was visible. The 
M3 method did not improve the observed under-predic-
tion at low concentrations either. Nonetheless, the model 
adequately described the central tendency and dispersion 
of the observed data appropriately (Fig S1 in supplemen-
tary materials). Concentration–time plots of individual 
patients in brain also indicated that model had appro-
priately described the data (Fig S2). Bootstrap results 
(Table 3) indicated that PK parameter estimates were sta-
ble. Both eta and epsilon shrinkages were below 20% on 
all parameters of the final model. The condition number 
representing model identifiability was 11.23.
Probability of Target Attainment
MCS indicated that the probability of target attainment 
was more than 90% for MICs up to 0.5 mg/L for all three 
simulated doses (12, 16, and 24 g per day). For a MIC of 
1  mg/L, PTA was more than 90% only for the doses of 
24 g per 24 h. All three types of infusion performed simi-
larly with respect to PTA over the dose range of 12–24 g 
per day (Fig. 4). These results were not significantly dif-
ferent when other plasma models were used (Fig. 4 and 
Fig S3 in supplementary materials).
Discussion
This study quantified the concentrations of piperacillin 
in the interstitial fluid of brain and generated a PopPK 
model to describe its pharmacokinetics. MCS sug-
gests that similar CNS exposures are attained in brain 
ECF with different types of infusion. Furthermore, our 
results infer that only highly susceptible pathogen can be 
empirically treated successfully by piperacillin in brain in 
patients without meningeal inflammation.
The similar piperacillin exposure and related PTA in 
brain with different types of infusion are an interesting 
finding (Fig.  4) because many studies based on plasma 
data have shown superiority of continuous and pro-
longed infusion over intermittent infusions with regard 
to PTA in various cohorts of patients including critically 
ill patients [9, 10]. This result is readily explained by the 
observation that fluctuations of plasma concentrations 
are dampened considerably by the transport of the drug 
to and from the brain, thus mimicking kind of a continu-
ous infusion for the brain. Therefore, continuous infu-
sion would not provide any pharmacokinetic benefit over 
intermittent infusion to achieve appropriate piperacillin 
brain concentrations in patients without general menin-
geal inflammation. This may also apply for other, mainly 
hydrophilic, anti-bacterials with slow transport into and 
from the brain and for other tissues with low transfer 
rates from and to the plasma.
Piperacillin is an anti-pseudomonal penicillin deriva-
tive mainly used to treat nosocomial pathogens such as 
Pseudomonas aeruginosa. However, based on a daily dose 
of 12 g of piperacillin, maximum observed brain concen-
trations after multiple doses (i.e., about 7.5  mg/L) were 
far below the concentration expected to be successful in 
treating P. aeruginosa (Table 2). For the same daily dose, 
MCS showed that the pharmacodynamic target in brain 
is only achieved for bacteria up to a MIC of 0.5  mg/L, 
and thus, infections involving only highly susceptible 
pathogens (Table 2) could be treated with this commonly 
used dosing regimen. Using higher doses (16–24  g/day) 
only achieved an acceptable PTA up to a MIC of 1 mg/L. 
This shows that increasing the dose up to the maximum 
recommended doses might still not be sufficient to treat 
CNS infections caused by pathogens with higher MICs 
(Table  2). Thus, piperacillin might not be an option for 
prophylaxis for invasive neurosurgical procedures, 
despite of some previous evidence supporting its use [28]. 
As an additional problem for its potential use, high vari-
ability in piperacillin brain pharmacokinetics was found 
(Fig S1) which is similar to plasma data where a high vari-
ability has also been reported in critically ill patients of 
various populations [10, 27, 29–31]. Having said this, it 
is important to mention that brain exposure of piperacil-
lin in meningitis patients is expected to be higher than 
in hemorrhagic stroke patients because only a small part 
of the brain is affected as compared to meningitis where 
the blood–brain barrier is disrupted based on the gener-
alized inflammation [32].
An important consideration for the interpretation of 
our results is that tazobactam concentrations were not 
Table 3 Pharmacokinetic parameters of  the brain model 
of piperacillin
Kpb, Kbp_fd, and Kbp_md represent rate of transfer from plasma to brain, transfer 
rate from brain to plasma after first dose, and transfer rate from brain to plasma 
after multiple doses, respectively. Tlag_fd and Tlag_md represent lag time after first 
and multiple doses, respectively
CI confidence interval, CV coefficient of variation, SD standard deviation
Parameter Bootstrap estimates 
(samples = 1000) (median 
[95% CI])
Fixed effects
 Kpb  (h
−1) 0.32 (0.16–0.39)
 Kbp_fd  (h
−1) 7.31 (3.47–12.9)
 Kbp_md  (h
−1) 4.39 (1.35–10.6)
 Tlag_fd (h) 2.70 (2.21–3.52)
 Tlag_md (h) 0 FIXED
Inter-individual variability (CV %)
 Tlag 19.7 (5.0–33.6)
Residual variability (SD)
 Additive error 0.03 (0.02–0.03)
 Proportional error 0.35 (0.23–0.44)
Fig. 3 Combined goodness-of-fit plots of the piperacillin brain concentrations. Individual predictions versus observed concentrations (upper left), 
population predictions vs. observed concentration (upper right), population predictions versus conditional weighted residuals (lower left), and time 
after dose versus conditional weighted residuals (lower right)
Fig. 4 Plots showing probability of target attainment in brain at various doses and MIC levels for different forms of infusion using plasma model 
from Roberts et al. [10]
quantifiable. MICs of piperacillin are typically higher 
than MICs of piperacillin/tazobactam for several patho-
gens, especially for beta-lactamase producers [33]. In the 
worst case, tazobactam would not reach the brain and the 
higher MICs of piperacillin rather than MICs of pipera-
cillin/tazobactam would apply. It is generally believed 
that piperacillin and tazobactam exhibit similar phar-
macokinetics [34] and tazobactam does not affect the 
pharmacokinetic behavior of piperacillin [35]. However, 
piperacillin inhibits the cumulative urinary excretion 
of tazobactam (mediated through OATs transporters) 
thereby increasing its plasma concentrations [36]. In 
addition, a recent study reported a high variability in the 
ratio of piperacillin over tazobactam (ranging from 1 to 
10) despite of their high correlation (0.93) [37]. We spec-
ulate that this variability might be even higher in brain as 
compared to the plasma data.
Because microdialysis in  vivo recovery experiments 
could not be carried out due to retrospective nature of 
the study, brain data were fitted on the basis of in vitro 
recovery of piperacillin. However, there is some evidence 
that in  vivo recovery might slightly differ from in  vitro, 
usually with lower values in  vivo [38]. However, at low 
flow rates for hydrophilic molecules with relatively low 
molecular weight like piperacillin, high recovery can be 
expected. Therefore, the low flow rate used in our study 
(0.3  µL/min) would explain why our in  vitro recovery 
values are higher as compared to in vivo values (8–40%) 
reported in the literature [39–41] where flow rates of 
1.5–2 µL/min were used. Thus, PTA values estimated in 
the present study with the assumption of a recovery of 
100% are a realistic, albeit conservative estimate. Simi-
larly, we could not estimate brain penetration from area 
under the concentration time curve (AUC) ratio between 
brain and plasma (AUC brain/AUC plasma) of piperacillin 
due to the lack of plasma data. However, the unavailabil-
ity of plasma concentrations is not relevant for PTA esti-
mations as also supported by the sensitivity analysis (Fig. 
S3). Additionally, our simulation results are based on 
pharmacodynamic targets validated in plasma as brain 
targets were not available. Small sample size and the 
presence of BQL values were among the other limitations 
of our study.
Conclusion
In conclusion, piperacillin exposure to brain is delayed 
after initial intravenous infusion, and concentration pro-
files would be expected to remain similar to different 
durations of infusion. The results suggest that piperacillin 
would not be appropriate in most CNS infections, in par-
ticular, in pseudomonas CNS infections.
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